Risk of thrombosis and bleeding following CAR T‐cell therapy: Insights from the Dutch “Follow that CAR!” registry
Amica Ko, Pim G. N. J. Mutsaers, Lukas Van Kleij, Amária Vledder et autres
Abstract Chimeric antigen receptor (CAR) T‐cell therapy has significantly improved outcomes in patients with relapsed/refractory aggressive large B‐cell lymphoma (R/R LBCL). Although thrombosis and bleeding complications have been increasingly reported, their clinical relevance and risk factors remain unclear, also due to heterogeneity …
nl (code pays fourni par la source)